Cancer researchers at Cedars-Sinai say they've found an important biomarker among the small group of patients that respond to gefitinib, or Iressa. A protein called EMP-1 is present among the patients who don't respond. Researchers have been working on finding out why a group of patients respond to Iressa while others receive no benefit. These molecular clues are considered key to determining better who would benefit from the treatment.
- read this article from Medical News Today for more